Hydrotalcite Anhydrous

Summary

Hydrotalcite Anhydrous (CHEMBL3833409) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 531.92 Da · CH16Al2Mg6O19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833409
Name	Hydrotalcite Anhydrous
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	159347
Molecular formula	CH16Al2Mg6O19
Molecular weight	531.92
InChIKey	GDVKFRBCXAPAQJ-UHFFFAOYSA-A

SMILES: C(=O)([O-])[O-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3]

IUPAC name: dialuminum;hexamagnesium;carbonate;hexadecahydroxide

Parent form; salt/anhydrous children: CHEMBL3833351

Patent coverage: 172 distinct patent families (580 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).